newsfilter
← Latest News
PR Newswire·

Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates

AZTR
  • Azitra, Inc. reported financial results for the quarter ended June 30, 2026, alongside a business update.
  • Preclinical data for ATR-COSF demonstrated breakthrough repeat-dose distribution, controlled delivery into skin layers, and anti-wrinkle activity in ex vivo human skin.
  • ATR-COSF human cosmetic application study is planned to commence in Q3 2026.
  • Enrollment continued for the first cohort of the Phase 1/2 clinical trial for ATR-04 targeting EGFR inhibitor-associated rash, with six active sites including MD Anderson Cancer Center.
  • Topline data from the first cohort of the ATR-04 Phase 1/2 trial is expected in Q4 2026.
  • Azitra announced plans to advance its recombinant protein platform, including TEV Protease and T7 RNA Polymerase, for biotechnology research.
  • Development of the ATR-12 Phase 1b trial for Netherton syndrome was strategically paused to focus capital on near-term opportunities.
  • Research and development expenses were $1.4 million for the quarter, compared to $1.4 million in the same period of 2025.
  • General and administrative expenses increased to $2.1 million from $1.5 million in the prior year period.
  • The net loss for the quarter was $3.3 million, compared to $2.9 million in 2025.
  • Cash and cash equivalents stood at $6.7 million as of June 30, 2026.
  • CEO Francisco Salva highlighted the expansion of the company's strategy across therapeutics, cosmetic ingredients, and biotechnology applications.